Results 41 to 50 of about 4,245 (206)

Meeting Notes of the Taiwan Neuroendocrine Tumor Society & Taiwan Society of Nuclear Medicine Joint Conference - Peptide Receptor Radionuclide Therapy Targeting for Gastroenteropancreatic Neuroendocrine Tumors: Basic Principles and State-of-the-art Clinical Practice

Journal of Cancer Research and Practice
Objective: The current study aimed to investigate the basic principles and clinical applications, including the selection of proper candidates, follow-up strategies, and radiation protection issues relating to peptide receptor radionuclide therapy (PRRT).
Mei-Fang Cheng, Chih-Chieh Yen, Jeng-Shiun Du, Yu-Li Chiu, Ming-Huang Chen, Hui-Jen Tsai, I-Chen Wu, Hueng-Yuan Shen, Ruoh-Fang Yen, Li-Tzong Chen, On Behalf of Taiwan Neuroendocrine Tumor Society and Taiwan Society of Nuclear Medicine   +10 more
doaj   +1 more source

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

Endocrine Connections, 2019
In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data are available on peptide receptor radionuclide ...
G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, S Cannavò   +10 more
doaj   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate

, 2011
Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs), with outstanding overall response rates and survival.
Samer Ezziddin, Tobias Höller, Christian Boy, Sabet, Amir, Guhlke, Stefan, Biersack, Hans-Jürgen, Willinek, Winfried, Hans-Jürgen Biersack, Stefan Guhlke, Ezziddin, Samer, Höller, Tobias, Hojjat Ahmadzadehfar, Yong-Hing, Charlotte J, Boy, Christian, Heinemann, Florian, Ahmadzadehfar, Hojjat, Charlotte J. Yong-Hing, Winfried Willinek, Florian Heinemann, Amir Sabet   +19 more
core   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib [PDF]

, 2023
Peptide receptor radionuclide therapy (PRRT), a form of internal targeted radiation treatment using [177Lu]Lu [DOTA0-Tyr3]octreotate, is used to treat patients with metastasized neuroendocrine tumors (NETs).
Corrina de Ridder, Danny Feijtel, Nicole Verkaik, de Jong, Marion, Feijtel, Danny, Christine van Tuyll-van Serooskerken, Debra Stuurman, van Tuyll-van Serooskerken, Christine, Thom Reuvers, Peter de Bruijn, Stuurman, Debra C, Koolen, Stijn L W, Reuvers, Thom G A, Nonnekens, Julie; id_orcid, Erik de Blois, Julie Nonnekens, Verkaik, Nicole S, de Bruijn, Peter, de Blois, Erik, Nonnekens, Julie, Stijn Koolen, de Ridder, Corrina M A, Marion de Jong   +22 more
core   +1 more source

Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

BMC Cancer, 2020
Background There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR).
Espen Thiis-Evensen, Amalie Christine Poole, Hong-Thien Thi Nguyen, Jon Sponheim   +3 more
doaj   +1 more source

Supplementary Material for: Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation

, 2017
Background: Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been ...
Zaniboni A. (4135816), Rodella C. (4135813), Nisa L. (4135807), Bertagna F. (4135801), Bettinsoli G. (4135819), Biasiotto G. (4135810), Bosio G. (4135822), Peli A. (4135825), Savelli G. (4135828), Migliorati E. (4135804)   +9 more
core   +1 more source

Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications

Frontiers in Oncology
Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by excessive gastric acid secretion due to gastrin-producing neuroendocrine tumors.
Martina Di Franco, Rexhep Durmo, Maria Liberata Di Paolo, Roberto Giacosa, Elisa Bannò, Valentina Ambrosini, Valentina Ambrosini, Angelina Filice   +7 more
doaj   +1 more source